Adventrx News (AMEX:ANX)
| Latest ADVENTRX PHARMACEUTICALS News Headlines | | Date | Time | Source | | | 05/16/2008 | 6:00AM | PRNUS | ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
- ANX-530 Demonstrates Statistically Significant Reductions in Selected Safety Observations
SAN DIEGO, May 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) announced today that, in a registrational bioequivalence clinical study, ANX-530 demonstrated a statistically significant reduction in general... More...>> |
| 05/13/2008 | 6:00AM | PRNUS | ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
SAN DIEGO, May 13 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced that Evan M. Levine, ADVENTRX's Chief Executive Officer and President, is scheduled to present at the Rodman & Renshaw 5th Annual Global Healthcare Conference. Mr. Levine is scheduled to present on Tuesday, May 20... More...>> |
| 05/12/2008 | 6:00AM | PRNUS | ADVENTRX Pharmaceuticals Reports First Quarter 2008 Financial Results
Conference call scheduled for May 12, 2008 at 1:30 p.m. (Pacific Time); simultaneous webcast at www.adventrx.com
SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily... More...>> |
| 05/05/2008 | 6:00AM | PRNUS | ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results
Conference call scheduled for May 12, 2008 at 1:30 p.m. (Pacific); simultaneous webcast at http://www.adventrx.com
SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced that it will host a conference call with simultaneous webcast to discuss first quarter 2008 results on... More...>> |
| 04/15/2008 | 6:00AM | PRNUS | ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
ADVENTRX Presents Data at the 2008 American Association for Cancer Research Annual Meeting
SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) announced that it presented pharmacokinetic data from its registrational bioequivalence clinical study of ANX-530 (vinorelbine emulsion) at... More...>> |
| 04/09/2008 | 6:00AM | PRNUS | ADVENTRX Appoints Vice President of Manufacturing
SAN DIEGO, April 9, 2008 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) announced today that it has appointed Jose Hechavarria to the new position of vice president of manufacturing. Mr. Hechavarria will be responsible for leading the company's planned commercial manufacturing operations.
"We are... More...>> |
| 04/03/2008 | 3:00PM | PRNUS | ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer
SAN DIEGO, April 3, 2008 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) announced today that Mark Bagnall, a member of the Company's Board of Directors, has joined the Company as Executive Vice President, a newly created position, and Chief Financial Officer. As Executive Vice President, Mr. Bagnall... More...>> |
| 03/31/2008 | 6:00AM | PRNUS | ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests
ADVENTRX Presents Results at Keystone Symposia HIV Pathogenesis Conference
SAN DIEGO, March 31 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) announced that it presented preclinical results for ANX-201, the Company's broad-spectrum antiviral product candidate at the Keystone Symposia HIV Pathogenesis... More...>> |
| 03/13/2008 | 4:01PM | PRNUS | ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Conference call scheduled for March 13 at 1:30 p.m. (Pacific Time); simultaneous webcast at http://www.adventrx.com
SAN DIEGO, March 13 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates... More...>> |
| 03/12/2008 | 6:00AM | PRNUS | ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology
SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) announced today that preliminary data from the Company's Phase 2 clinical study of ANX-510, CoFactor(R), for the treatment of advanced breast cancer has been accepted for presentation at the 2008 American Society of Clinical Oncology... More...>> |
| 03/10/2008 | 7:00AM | PRNUS | Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
SAN DIEGO, March 10 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) announced today that complete safety data from its registrational bioequivalence clinical study of ANX-530 (vinorelbine emulsion) will be published in the 2008 Proceedings of the American Society of Clinical Oncology (ASCO) in connection... More...>> |
| 03/06/2008 | 6:00AM | PRNUS | ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
Conference call scheduled for March 13, 2008 at 1:30 p.m. (Pacific); simultaneous webcast at www.adventrx.com
SAN DIEGO, March 6 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced that it will host a conference call and webcast on Thursday, March 13th, 2008 at 1:30 p.m. Pacific / 4:30... More...>> |
| 02/25/2008 | 6:00AM | PRNUS | Eric K. Rowinsky Joins ADVENTRX Board of Directors
SAN DIEGO, Feb. 25 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) announced today that Eric K. Rowinsky, M.D., Chief Medical Officer and Executive Vice President of ImClone Systems Incorporated, will join its Board of Directors. In connection with Dr. Rowinsky's appointment, ADVENTRX increased the... More...>> |
| 02/07/2008 | 6:00AM | PRNUS | ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
SAN DIEGO, Feb. 7 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX), announced today that complete pharmacokinetic data from the Company's marketing-enabling bioequivalence clinical study of ANX-530 (vinorelbine emulsion) has been accepted for presentation at the 2008 American Association for Cancer... More...>> |
| 02/05/2008 | 6:00AM | PRNUS | ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference
SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that Evan M. Levine, ADVENTRX's chief executive officer... More...>> |
| 01/31/2008 | 6:00AM | PRNUS | ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX), announced today that data from preclinical studies of ANX-201, the Company's broad spectrum antiviral product candidate, has been accepted for presentation at the Keystone Symposia HIV Pathogenesis Conference, which takes place March... More...>> |
| 01/30/2008 | 6:00AM | PRNUS | ADVENTRX Announces Consolidation of Clinical and Management Positions
SAN DIEGO, Jan. 30 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that Evan M. Levine, the company's current Chief... More...>> |
| 01/14/2008 | 6:30AM | PRNUS | ADVENTRX Announces ANX-530 Safety Data and Provides NDA Submission Guidance
ANX-530 Demonstrates Statistically Significant Reduction in Injection Site Reactions
SAN DIEGO, Jan. 14 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced safety results from its marketing-enabling bioequivalence clinical study of ANX-530 (vinorelbine emulsion). ANX-530 demonstrated... More...>> |
| 12/10/2007 | 6:00AM | PRNUS | ADVENTRX Pharmaceuticals to Present at the 2007 RBC Capital Markets Healthcare Conference
SAN DIEGO, Dec. 10 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that Brian M. Culley, ADVENTRX's chief business officer... More...>> |
| 12/05/2007 | 6:00AM | PRNUS | ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breas
SAN DIEGO, Dec. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that it has completed patient enrollment in its Phase... More...>> |
|
|
|